CN1046939C - 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 - Google Patents

氟烷氧基取代的苯甲酰胺类及其制备方法和应用 Download PDF

Info

Publication number
CN1046939C
CN1046939C CN94192659A CN94192659A CN1046939C CN 1046939 C CN1046939 C CN 1046939C CN 94192659 A CN94192659 A CN 94192659A CN 94192659 A CN94192659 A CN 94192659A CN 1046939 C CN1046939 C CN 1046939C
Authority
CN
China
Prior art keywords
halogen
alkyl
hydrogen
phenyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN94192659A
Other languages
English (en)
Chinese (zh)
Other versions
CN1126468A (zh
Inventor
H·阿施勒
D·弗洛克齐
B·古特勒
A·哈策曼
C·舒特
R·博默
U·吉利安
H·P·O·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4223466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1046939(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of CN1126468A publication Critical patent/CN1126468A/zh
Application granted granted Critical
Publication of CN1046939C publication Critical patent/CN1046939C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN94192659A 1993-07-02 1994-07-02 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 Expired - Lifetime CN1046939C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1996/93-9 1993-07-02
CH199693 1993-07-02
CH1996/939 1993-07-02

Publications (2)

Publication Number Publication Date
CN1126468A CN1126468A (zh) 1996-07-10
CN1046939C true CN1046939C (zh) 1999-12-01

Family

ID=4223466

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94192659A Expired - Lifetime CN1046939C (zh) 1993-07-02 1994-07-02 氟烷氧基取代的苯甲酰胺类及其制备方法和应用

Country Status (27)

Country Link
US (1) US5712298A (2)
EP (1) EP0706513B1 (2)
JP (1) JP3093271B2 (2)
KR (1) KR100331255B1 (2)
CN (1) CN1046939C (2)
AT (1) ATE217612T1 (2)
AU (1) AU687087B2 (2)
CA (1) CA2165192C (2)
CY (2) CY2389B1 (2)
CZ (1) CZ290266B6 (2)
DE (2) DE59410119D1 (2)
DK (1) DK0706513T3 (2)
ES (1) ES2176252T3 (2)
FI (1) FI112864B (2)
FR (1) FR10C0052I2 (2)
HU (1) HU220041B (2)
LU (1) LU91709I2 (2)
LV (1) LV13074B (2)
NO (2) NO305598B1 (2)
NZ (1) NZ271316A (2)
PL (1) PL178314B1 (2)
PT (1) PT706513E (2)
RU (1) RU2137754C1 (2)
SG (1) SG143011A1 (2)
SI (1) SI0706513T1 (2)
SK (1) SK283263B6 (2)
WO (1) WO1995001338A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690194A (zh) * 2011-03-24 2012-09-26 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN104080770A (zh) * 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
ATE229516T1 (de) * 1996-08-19 2002-12-15 Altana Pharma Ag Benzofuran-4-carboxamide
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6172118B1 (en) * 1998-04-14 2001-01-09 Smithkline Beecham Corporation Compounds
EP1161239B1 (en) 1999-03-10 2004-10-20 ALTANA Pharma AG 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
SI1176960T1 (en) * 1999-05-04 2005-04-30 Altana Pharma Ag Synergistic combination comprising roflumilast and a pde-3 inhibitor
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
DE10043074A1 (de) * 2000-09-01 2002-03-14 Aventis Cropscience Gmbh Herbizid wirksame Benzoylcyclohexandione
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
EP1397359B1 (en) 2001-05-24 2005-08-31 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
RU2227797C2 (ru) * 2002-03-29 2004-04-27 Пермская государственная фармацевтическая академия 4-метил-2-пиридиламид тетрахлорфталевой кислоты, проявляющий гипертензивную активность
JP2005528418A (ja) * 2002-05-07 2005-09-22 アルタナ　ファルマ　アクチエンゲゼルシャフト 気道疾患を治療するための新規組み合わせ
PL373000A1 (en) * 2002-05-07 2005-08-08 Altana Pharma Ag Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
MXPA04011335A (es) * 2002-05-16 2005-07-01 Pharmacia Corp Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
CA2492907A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
RU2354648C2 (ru) 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004021987A2 (en) * 2002-09-06 2004-03-18 Merck & Co., Inc. Treatment of rheumatoid arthritis by inhibition of pde4
BR0314603A (pt) * 2002-09-20 2005-07-26 Alcon Inc Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
US6822114B1 (en) * 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
WO2004037805A1 (en) 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
EP1569908B1 (en) * 2002-11-19 2010-09-15 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
BR0316451A (pt) * 2002-11-27 2005-10-11 Altana Pharma Ag Combinação sinergìstica compreendendo roflumilast e formoterol
TW200426138A (en) * 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
WO2004089940A1 (en) 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098597A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098595A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098598A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004103407A2 (en) 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
EP1670742A1 (en) * 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
WO2005046676A1 (en) * 2003-11-12 2005-05-26 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
PT1685849E (pt) 2003-11-20 2012-02-15 Astellas Pharma Inc Inibidores de pde4 para o tratamento da cistite intersticial
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AU2005210085B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
WO2005077906A1 (en) 2004-02-18 2005-08-25 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
EP1720543A1 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Roflumilast and glycopryrronium combination
SG182194A1 (en) 2004-03-03 2012-07-30 Nycomed Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
WO2006006741A1 (ja) 2004-07-15 2006-01-19 Japan Tobacco Inc. 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US20080085858A1 (en) * 2004-10-13 2008-04-10 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical Composition
WO2006040652A2 (en) 2004-10-13 2006-04-20 Glenmark Pharmaceuticals S.A. Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
EP1810692A1 (en) * 2004-10-13 2007-07-25 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
DK1831227T3 (da) 2004-12-17 2013-08-19 Glenmark Pharmaceuticals Sa Hidtil ukendte, heterocykliske forbindelser, der er anvendelige til behandling af inflammatoriske og allergiske forstyrrelser
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
AU2006224619B2 (en) 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
BRPI0610498A2 (pt) 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
EP1940392A2 (en) * 2005-05-11 2008-07-09 Nycomed GmbH Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
BRPI0617806A2 (pt) * 2005-10-24 2011-08-09 Novartis Ag combinação de inibidores de histona desacetilase com radiação
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20100056791A1 (en) 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
SI2148876T1 (sl) 2007-05-16 2012-01-31 Nycomed Gmbh Pirazolonski derivati kot PDE4 inhibitorji
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
JP5704924B2 (ja) 2008-02-01 2015-04-22 オーキッド リサーチ ラボラトリーズ リミティド 新規複素環化合物
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
NZ603895A (en) 2010-06-24 2014-10-31 Leo Pharma As Novel phosphodiesterase inhibitors
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102093194B (zh) * 2010-12-24 2014-01-08 江苏先声药物研究有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102276522B (zh) * 2011-06-15 2013-04-17 无锡泓兴生物医药科技有限公司 一种制备罗氟司特的方法及其中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
KR20140078719A (ko) * 2011-10-21 2014-06-25 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
WO2013081565A1 (en) 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
WO2013077830A1 (en) 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013131255A1 (en) 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103630613B (zh) * 2012-08-21 2015-08-05 北大方正集团有限公司 分离并检测罗氟司特及其中间体的方法
EP2909177B1 (en) 2012-10-17 2017-03-29 Interquim, S.A. Process for preparing roflumilast
LT2948148T (lt) * 2013-01-28 2020-12-28 Incozen Therapeutics Pvt. Ltd. Autoimuninių, kvėpavimo ir uždegiminių sutrikimų gydymo būdai, įkvėpiant roflumilasto n-oksidą
WO2014117947A1 (en) 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
MX2015009677A (es) 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida novedosos.
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
CN103304475A (zh) * 2013-06-13 2013-09-18 湖南千金湘江药业股份有限公司 苯甲酰胺化合物及其制备方法和用途
HUE035967T2 (hu) 2013-08-09 2018-06-28 Gruenenthal Gmbh Új helyettesített kondenzált pirimidinvegyületek
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
AR101197A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas
AR101196A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Compuestos de pirimidina sustituidos
AR101198A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
CN104130116B (zh) * 2014-08-18 2015-11-11 朱丽平 一种制备罗氟司特中间体的方法
CN106573889B (zh) 2014-10-24 2019-01-01 久光制药株式会社 前药
CN104447245B (zh) * 2014-10-29 2017-06-06 成都森科制药有限公司 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
KR20170034707A (ko) 2015-09-21 2017-03-29 한미약품 주식회사 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN105523954B (zh) * 2016-02-05 2017-07-18 徐江平 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
HRP20251042T1 (hr) 2017-10-23 2025-10-24 Boehringer Ingelheim International Gmbh Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild)
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN115551478A (zh) 2020-01-31 2022-12-30 阿尔库缇斯生物疗法股份有限公司 具有改善递送和血浆半衰期的罗氟司特局部制剂
CN115397411B (zh) 2020-04-23 2025-08-22 浙江养生堂天然药物研究所有限公司 药物组合及其用途
CN111777550A (zh) * 2020-06-01 2020-10-16 山东希尔康泰药业有限公司 罗氟司特结晶性粉末原料药生产制备方法
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
EP4282413A4 (en) * 2021-01-21 2024-12-25 Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. COMPOSITION AND METHOD FOR TREATING TUMORS
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
CN119013001A (zh) 2021-12-28 2024-11-22 阿尔库缇斯生物疗法股份有限公司 局部气溶胶泡沫
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
US20250082618A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
WO2025059531A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Topical roflumilast for the treatment of atopic/seborrheic dermatitis
WO2025265054A2 (en) 2024-06-21 2025-12-26 Arcutis Biotherapeutics, Inc. Methods of treatment using topical roflumilast compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0120352A1 (de) * 1983-03-09 1984-10-03 BASF Aktiengesellschaft N-Acyl-anthranilsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
WO1992012961A1 (en) * 1991-01-28 1992-08-06 Rhone Poulenc Rorer Limited Benzamides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
JPS62158253A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
SU1512053A1 (ru) * 1988-01-29 1991-01-15 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 2-Окси-3,5-дигалоид-N-[3-хлор-4-(4-галоиднафтокси-1)-фенил]-бензамиды, обладающие активностью при экспериментальном описторхозе и гименолепидозе
EP0510562A1 (de) * 1991-04-26 1992-10-28 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Pyridazine
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
ATE150447T1 (de) * 1992-06-15 1997-04-15 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
ES2227519T3 (es) * 1992-07-28 2005-04-01 Aventis Pharma Limited Inhibidores de c-amp-fosfodiesterasa.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0120352A1 (de) * 1983-03-09 1984-10-03 BASF Aktiengesellschaft N-Acyl-anthranilsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
WO1992012961A1 (en) * 1991-01-28 1992-08-06 Rhone Poulenc Rorer Limited Benzamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAVOI98 1983. 1. 1 FIALKOV,YU,A,SHLGO,ZGENKO,S,V,DUBUR,G,YE,UOSTRON,V,V,:DIFLUO ROMETHOXQDE *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690194A (zh) * 2011-03-24 2012-09-26 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN102690194B (zh) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN104080770A (zh) * 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法

Also Published As

Publication number Publication date
NO955211L (no) 1995-12-21
FI956333A7 (fi) 1995-12-29
NO305598B1 (no) 1999-06-28
SI0706513T1 (en) 2002-10-31
NZ271316A (en) 1997-11-24
US5712298A (en) 1998-01-27
CA2165192A1 (en) 1995-01-12
KR100331255B1 (ko) 2002-10-25
EP0706513B1 (de) 2002-05-15
HUT73232A (en) 1996-07-29
AU687087B2 (en) 1998-02-19
SG143011A1 (en) 2008-06-27
FI112864B (fi) 2004-01-30
AU7490794A (en) 1995-01-24
WO1995001338A1 (de) 1995-01-12
LU91709I2 (fr) 2010-09-21
HK1011690A1 (en) 1999-07-16
SK283263B6 (sk) 2003-04-01
NO955211D0 (no) 1995-12-21
DE122010000043I1 (de) 2011-01-27
SK161795A3 (en) 1996-07-03
CZ196A3 (en) 1996-06-12
CY2010015I2 (el) 2011-02-02
DE59410119D1 (de) 2002-06-20
LV13074B (en) 2004-03-20
HU9503541D0 (en) 1996-02-28
PT706513E (pt) 2002-10-31
CA2165192C (en) 2001-04-24
PL178314B1 (pl) 2000-04-28
FR10C0052I1 (2) 2011-01-14
HU220041B (hu) 2001-10-28
CY2389B1 (en) 2004-09-10
ATE217612T1 (de) 2002-06-15
RU2137754C1 (ru) 1999-09-20
ES2176252T3 (es) 2002-12-01
CN1126468A (zh) 1996-07-10
JP3093271B2 (ja) 2000-10-03
CY2010015I1 (el) 2011-02-02
FR10C0052I2 (2) 2011-11-25
PL311820A1 (en) 1996-03-18
FI956333A0 (fi) 1995-12-29
CZ290266B6 (cs) 2002-06-12
EP0706513A1 (de) 1996-04-17
KR960703400A (ko) 1996-08-17
NO2010018I1 (no) 2010-10-18
NO2010018I2 (2) 2011-10-17
JPH08512041A (ja) 1996-12-17
DK0706513T3 (da) 2002-09-09

Similar Documents

Publication Publication Date Title
RU2137754C1 (ru) Фторалкоксизамещенные бензамиды, способ их получения и фармацевтическая композиция на их основе
JP4146894B2 (ja) ジヒドロベンゾフラン
CN1671695A (zh) 用作pde4抑制剂的吡咯烷二酮取代的哌啶－2,3－二氮杂萘酮化合物
CN1336919A (zh) 具有pde－iv抑制活性的苯基菲啶类化合物
CN1496257A (zh) 调控免疫球蛋白e及抑制细胞增殖的苯并咪唑化合物
CN1422269A (zh) 1h－咪唑并吡啶衍生物
CN1524080A (zh) 作为pde4抑制剂的2,3-二氮杂萘酮哌啶子基衍生物
CN1265098A (zh) 抑制因子xa的杂环衍生物
US6303789B1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
EA014324B1 (ru) Триазолофталазины
CN1146562C (zh) 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
US5922871A (en) Terephthalamide derivatives
CN1258276A (zh) 细胞增生抑制剂氰基胍
CN101056870A (zh) 作为血管内皮生长因子（vegf）受体激酶抑制剂的新的烟酰胺吡啶脲
HK1048116A1 (zh) 苯甲酰基噠嗪
CN121568694A (zh) 恶性疟原虫红内期抑制剂
CN1610667A (zh) 新型3－硝基吡啶衍生物和含有该衍生物的药物组合物
CN1751043A (zh) 咪唑并(4,5－b)喹啉衍生物及其作为no－合酶抑制剂的应用
CA2195663C (en) Dihydrobenzofuranes
HK1088902A (en) Imidazo [4,5-b] quinoline-derivatives and their use as no-synthase inhibitors
HK1027570A (en) Cyanoguanidines as cell proliferation inhibitors
HK1011690B (en) Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
HK1027351A (en) Cyanoamidines as cell proliferation inhibitors
HK1068826A (en) 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: OTANA MEDICINE AG

Free format text: FORMER NAME OR ADDRESS: BYK GULDEN LOMBERG CHEM CO.

CP01 Change in the name or title of a patent holder

Patentee after: ALTANA PHARMA AG

Patentee before: BYK GULDEN LOMBERG CHEMISCHE FABRIK GmbH

C56 Change in the name or address of the patentee

Owner name: NICOMEDES LIMITED LIABILITY COMPANY

Free format text: FORMER NAME OR ADDRESS: OTANA MEDICINE AG

CP01 Change in the name or title of a patent holder

Address after: The Federal Republic of Germany Konstanz

Patentee after: NYCOMED GmbH

Address before: The Federal Republic of Germany Konstanz

Patentee before: ALTANA PHARMA AG

C56 Change in the name or address of the patentee

Owner name: NYCOMED INC.

Free format text: FORMER NAME: NYCOMED GMBH

CP03 Change of name, title or address

Address after: Konstanz

Patentee after: NYCOMED GmbH

Address before: The Federal Republic of Germany Konstanz

Patentee before: Nycomed GmbH

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20140702

Granted publication date: 19991201